title: Toward the next generation of NK cell-based adoptive cancer immunotherapy.
abstract: The adoptive transfer of interleukin (IL)-2-expanded natural killer (NK) cells has provided unsatisfactory clinical benefits to patients affected by solid tumors. Our study demonstrates that the activation of NK cells with IL-12/IL-15/IL-18 prior to transfer into tumor-bearing mice is critical for obtaining high recovery rates, effector functions in vivo and tumor regression.
authors.affiliation: German Cancer Research Center (DKFZ); Junior Research Group Innate Immunity; Heidelberg, Germany.
authors.forename: Jing
authors.initials: J
authors.lastname: Ni
authors.forename: Matthias
authors.initials: M
authors.lastname: Miller
authors.forename: Ana
authors.initials: A
authors.lastname: Stojanovic
authors.forename: Adelheid
authors.initials: A
authors.lastname: Cerwenka
keywords: CD4+ T cells; cancer; immunotherapy; natural killer cells; radiation therapy